VYGR Voyager Therapeutics Inc.

Voyager Therapeutics to Participate in Upcoming Investor Conferences

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following investor conferences:

  • Chardan’s 6th Annual Genetic Medicines Conference, New York, NY – Company presentation, October 4, 2022, 3:45 p.m. ET
  • Truist Securities Genetic Medicine Summit, New York, NY – CNS panel discussion (not webcast), October 20, 2022

The presentation may be accessed from the Investors section of Voyager’s website at . Replays of webcasts are archived on the Company's website for at least 30 days.

About Voyager Therapeutics 

Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from Voyager’s TRACER capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.

                 

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 



Contacts 
Investors 
  

Media   
Peg Rusconi 
  
EN
27/09/2022

Underlying

VYGRVoyager Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Voyager Therapeutics Inc.

David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
12/02/25 December 2, 2025 1 EN
Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
SMCI SUPER MICRO COMPUTER
ZNTL INC.
TLS ZENTALIS PHARMACEUTICALS
STX TELOS
GFS SEAGATE TECHNOLOGY HLDGS PLC
GETY GLOBALFOUNDRIES INC
DDI GETTY IMAGES HOLDINGS INC
DOUBLEDOWN INTERACTIVE CO LTD
11/11/25 November 11, 2025 1 EN
Yun Zhong
  • Yun Zhong
VYGR VOYAGER THERAPEUTICS INC.
RCKT ROCKET PHARMACEUTICALS
11/11/25 November 11, 2025 1 EN
 PRESS RELEASE
Free
VYGR Voyager Therape...

Transition Bio and Voyager Announce Collaboration to Advance Small Mol...

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to dis...

November 10, 2025 1 EN
 PRESS RELEASE
Free
VYGR Voyager Therape...

Voyager Reports Third Quarter 2025 Financial and Operating Results

Voyager Reports Third Quarter 2025 Financial and Operating Results - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -  - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today repo...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch